COMPARISON
Pramlintide vs Tirzepatide
5 attributes held for at least one of the two. 5 differ. Each value carries the register it came from and the date that register was read.
Answer
Pramlintide is authorised or registered in 1 and Tirzepatide in 10 of the 10 registers read. Pramlintide: highest phase Phase 3 (1 phase 3 trial, 0 with posted results). Tirzepatide: highest phase Phase 4 (after approval). 0 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Pramlintide | Tirzepatide | |
|---|---|---|
| Registered trials differs | 65 clinicaltrials.gov · 2026-10-03 | 309 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: SymlinPen openfda · 2026-10-03T17:23:44.062Z | FDA-approved: MOUNJARO openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation differs | Nothing on record ema read 2026-08-31 | Authorised ema · 2026-10-03 |
| EU authorised on differs | Not checked no record of "authorisedOn" for pramlintide | 2022-09-15 ema · 2026-10-03 |
| ATC code differs | Not checked no record of "atcCode" for pramlintide | A10BX16 ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Pramlintide | placebo | Tirzepatide | placebo |
|---|---|---|---|---|
| nausea | 28.5% | 4.7% | 25.6% | 8.1% |
| Upper respiratory tract infection | 12.1% | 10.4% | 5.7% | 6.2% |
| injection site pruritus | 14.7% | 0.7% | - | - |
| injection site erythema | 14.5% | 0.9% | - | - |
| injection site bruising | 11.2% | 12.3% | - | - |
| injection site hemorrhage | 11.2% | 3.8% | - | - |
| injection site rash | 8.9% | 0.0% | - | - |
| injection site urticaria | 8.3% | 0.0% | - | - |
| nasopharyngitis | 6.6% | 7.5% | - | - |
| injection site nodule | 5.9% | 3.8% | - | - |
| Diarrhoea | - | - | 21.2% | 8.3% |
| Covid-19 | - | - | 15.5% | 16.0% |
| Constipation | - | - | 13.7% | 4.5% |
| Decreased appetite | - | - | 11.6% | 2.9% |
| Vomiting | - | - | 11.4% | 2.6% |
| Dyspepsia | - | - | 7.9% | 2.7% |
| Headache | - | - | 6.6% | 6.2% |
| Abdominal pain | - | - | 6.0% | 2.7% |
Trial register Pramlintide: 5 placebo-controlled trials; Tirzepatide: 19. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Pramlintide side effects · Tirzepatide side effects
LEGAL STATUS
Approval in each country read
| Country | Pramlintide | Tirzepatide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Not on the register | Authorised | Regulator EMA |
| United Kingdom | Not on the register | Authorised | Regulator MHRA |
| Canada | Not on the register | Authorised | Regulator Health Canada |
| Australia | Status unknown | Registered | TGA |
| Switzerland | Not on the register | Authorised | Regulator Swissmedic |
| Brazil | Not on the register | Registado | Regulator ANVISA |
| Serbia | Not on the register | Authorised | Regulator ALIMS |
| Singapore | Not on the register | Registered | Regulator HSA |
| Turkey | Not on the register | Ruhsatli | Regulator TITCK |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.